Compare Pfizer Inc (PFE) vs STMicroelectronics NV (STM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs STMicroelectronics NV — how do they compare? Pfizer Inc trades at $27.74 (market cap $159.59B), while STMicroelectronics NV trades at $53.9 (market cap $50.29B). The key difference: Pfizer Inc is far larger — about 3.2× STMicroelectronics NV's market cap, and Pfizer Inc pays the higher dividend (6.14%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and STMicroelectronics NV for 66 Days on average.
| PFE | STM | |
|---|---|---|
Market Cap | $159.59B | $50.29B |
Volume | 30,937,010 | 9,536,788 |
Sector | Health | Technology |
52-Week High | $29.02 | $79.91 |
52-Week Low | $23.67 | $21.20 |
Typical Hold Time | 158 Days | 66 Days |
Enterprise Value | $211.09B | $47.81B |
Dividend Yield | 6.14% | 0.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
STM (STMicroelectronics) trades at $52.71, down 10.24% in the last session. The stock shows a bullish technical signal with moving averages supporting an uptrend, though oscillators are neutral. Fundamentally, revenue declined to $11.80B in 2025 with a net income margin of -0.39%, but recent Q2 2026 earnings beat expectations. Analyst sentiment is positive with a consensus price target of $77.31. Recent news highlights recovery in automotive and industrial demand, with AI data-center revenue projected to exceed $2B by 2027.
The outlook for STM hinges on execution in AI and automotive segments, offering growth potential, but risks include margin pressures from fab transitions and competitive threats. Wall Street's buy rating majority (51.72%) reflects optimism, though investors should monitor earnings consistency and debt levels, with the stock trading below consensus target indicating potential upside if recovery sustains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
